NuCana (NCNA) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NuCana is the larger company by market cap ($3.6 million vs $3.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCNA | XTLB |
|---|---|---|
| Share price | $0.7495 | $1.37 |
| Market cap | $3.61M | $3.37M |
| 1-day change | +4.39% | -5.84% |
| EPS (TTM) | $0.00 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $451.00K |
| Net income (latest FY) | — | $-1.03M |
| Gross margin | — | 0.67% |
| Operating margin | — | -481.60% |
| Net margin | — | -227.72% |
| 52-week high | $4.55 | $5.64 |
| 52-week low | $0.62 | $1.37 |
| Distance from 52-week high | -83.53% | -75.71% |
| Average volume | 118.13K | 6.58K |
| Shares outstanding | 4.82M | 2.46M |
| Employees | 10 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NuCana
NCNA stock →NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NCNA vs XTLB FAQ
Which is bigger, NuCana or XTL Biopharmaceuticals?
NuCana (NCNA) is larger, with a market capitalization of $3.61M compared with $3.37M for XTL Biopharmaceuticals (XTLB).
Are NuCana and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.